CClinicalTrials.gg
WithdrawnNCT03874845Updated Oct 23, 2023

Neural Mechanisms of Mindfulness-based Cognitive Therapy (MBCT) for Posttraumatic Stress Disorder (PTSD)_VA Only

An interventional study of Mindfulness-Based Cognitive Therapy and Muscle Relaxation Therapy in Post Traumatic Stress Disorder, sponsored by Ohio State University. Withdrawn at 2 sites in United States. Open to participants aged 18 Years to 72 Years. Per ClinicalTrials.gov, last updated 2023-10-23.

Sponsored by Ohio State University · Not applicable, Interventional, and Treatment

Why this study was withdrawn
Study had IRB approval from VA and began in late Feb 2020, did not enroll any participants before paused during the COVID. Final permissions from VA to restart recruitment was never received and therefore was withdrawn.
Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 72 Years
Sex
All
01

Study summary

This study will examine the effects of psychotherapy as treatment for PTSD. This research will see how brain activity and brain connectivity is affected by Mindfulness Based Cognitive Therapy (MBCT) and Muscle Relaxation Therapy (MRT). Participants that qualify to be in this study will receive 8 weeks of group therapy in MBCT or MRT. Prior to receiving therapy participants will: complete baseline assessments related to their PTSD; fill out surveys; have an functional magnetic resonance imaging (fMRI); and provide a saliva sample. These assessments will be repeated after the therapy is over. Overall study participation should last approximately 10-12 weeks.

Read the detailed description

Note: due to COVID precautions, treatment shifted from in-person to remote ("Zoom" videoconferencing)

02

Conditions studied

  • Post Traumatic Stress Disorder

Keywords

  • Mindfulness-Based Cognitive Therapy
  • Muscle Relaxation
  • fMRI
  • Group Psychotherapy
03

In context

Stress Disorders, Traumatic

1,147 studies on the registry are indexed under Stress Disorders, Traumatic; 108 are open to participants now.

Browse Stress Disorders, Traumatic studies →

Lead sponsor

Ohio State University is the lead sponsor of 640 studies on the registry; 144 are open to participants now.

Of its 60 completed or terminated interventional studies of FDA-regulated products, 45 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 72 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Meets current Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5) criteria for PTSD (with or without Major Depressive Disorder) or subsyndromal PTSD (qualifying trauma, and at least one intrusive, one avoidant, one negativity, and one arousal symptoms, and significant impairment or distress); type of trauma shall include interpersonal violence - combat, physical assault, sexual assault, etc.

Exclusion criteria

Exclusion Criteria:

  • Dissociative PTSD
  • Delayed-onset PTSD
  • Magnetic Resonance Imaging (MRI) contraindications (e.g. metal in body, inability to be in the scanner - claustrophobia, severe back pain, etc.)
  • Serious medical or neurologic conditions (e.g. stroke, seizures)
  • Suicide risk
  • Psychosis
  • Life history of schizophrenia
  • Life history of bipolar disorder
  • Current severe substance use disorder
  • Other factors that preclude safe and meaningful participation in the study, at discretion of the PI and study team
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Mindfulness-Based Cognitive Therapy

    Participants will have 8 weeks of group therapy and will be asked to do MBCT exercises for approximately 20-30 minutes on 5 or more days/week.

    Behavioral: Mindfulness-Based Cognitive Therapy

  • Active comparator
    Muscle Relaxation Therapy (MRG)

    Participants will have 8 weeks of group therapy participants and will be asked to do MRG exercises for approximately 20-30 minutes on 5 or more days/week.

    Behavioral: Muscle Relaxation Therapy

Interventions

  • BehavioralMindfulness-Based Cognitive Therapy

    Participants will attend 8 weekly group therapy sessions. Prior to and after therapy participants will have assessments related to their PTSD, fill out surveys, and have an fMRI.

  • BehavioralMuscle Relaxation Therapy

    Participants will attend 8 weekly group therapy sessions. Prior to and after therapy participants will have assessments related to their PTSD, fill out surveys, and have an fMRI.

06

What researchers measure

Primary outcomes

  1. Group differences in the change in resting-state functional connectivity between two large-scale distributed functional connectivity networks: the Default Mode Network (DMN) and the Central Executive Network (CEN)

    Network functional connectivity will be measured through fMRI blood oxygen level dependent \[BOLD\] signal. Time-course of BOLD signal while participants are "resting" (not performing a task) will be used to identify patterns of functional connectivity between two large-scale neural networks DMN and CEN. We will use the Brain Basis Set methodology: creating a whole-brain correlation matrix between all combinations of hundreds of brain regions throughout the brain (a "connectome") followed by data-reduction methods (principle components analyses, PCA) to examine the structure of functional connectivity patterns between nodes of canonical intrinsic connectivity networks.

    Time frame: pre-therapy and post therapy (approximately 8 weeks)

Secondary outcomes

  1. Group differences in the change in resting-state functional connectivity between two large-scale distributed functional connectivity networks: the Default Mode Network (DMN) and the Salience Network (SN), measured through fMRI BOLD signal.

    Network functional connectivity will be measured through fMRI blood oxygen level dependent \[BOLD\] signal. Time-course of BOLD signal while participants are "resting" (not performing a task) will be used identify patterns of functional connectivity between two large-scale neural networks DMN and CEN using the Brain Basis Set methodology.

    Time frame: pre-therapy and post therapy (approximately 8 weeks)

07

Study locations

2 sites
  • VA Ann Arbor Healthcare System
    Ann Arbor, Michigan 48105, United States
  • The Ohio State University
    Columbus, Ohio 43210, United States
08

References and documents

Individual participant data

Plan to share: Yes — We plan to make available data from fMRI scans from human subjects initially to collaborators for independent replication / data pooling. We also plan to make the de-identified brain scans available to the broad scientific community, however, additional redaction steps may need to be made to brain scans to ensure subject confidentiality / inability to identify individuals from brain scans. Completely de-identified research data (redacted according to NIH practice to prevent disclosure of personal identifiers) which documents the research findings will be made available after the main findings from the finalized research dataset have been accepted for publication. And with approval of Dept Veterans Affairs Office of Research and Development.

Supporting information: Study protocol, Sap, Icf, Csr, Analytic code

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 23, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03874845
Lead sponsor
Ohio State University
Collaborators
National Institute of Mental Health (NIMH)
Responsible party
Anthony P King (Associate Professor of Psychiatry, Faculty Associate, Institute for Behavioral Medicine Research, Institute for Behavioral Medicine Research, Institute for Social Research, Ohio State University) — Principal investigator
First posted
Mar 14, 2019
Start date
Jan 29, 2022
Primary completion
Mar 30, 2023 (estimated)
Completion
Jun 1, 2023
Last update
Oct 23, 2023

Study contacts

Anthony King, Ph.D
principal investigator · University of Michigan and The Ohio State University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion